

Supplementary Figure S1




Figure S1. Radotinib HCl reduces α -synuclein PFF-induced c-Abl activation and p38 MAPK phosphorylation *in vivo*.

(A) Representative immunoblots with ventral midbrain tissue lysates in PBS and α -synuclein PFF stereotaxic injected mice treated with vehicle or Radotinib HCl and Nilotinib. (B) Quantification of the levels of pY245-c-Abl normalized to c-Abl. (C) Quantification of the levels of phospho-p38 MAPK normalized to p38 MAPK. Bars indicate mean \pm S.E.M. (n=4). Statistical significance was determined by using one-way ANOVA with Tukey's correction; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. n.s., not significant. Radotinib, Radotinib HCl. Nilo., Nilotinib.